Interim results for six months ended 31 March 2020

PDF


Press Release

by oxfordbiodynamics

Industry expert Dr Peter Pack, appointed as Non-Executive Chairman, succeeding Stephen Diggle

Press Release

by oxfordbiodynamics

Oxford BioDynamics biomarker platform is selected to help identify COVID-19 patients at risk of severe disease and profile patients who will benefit from therapeutic treatment

Press Release

by oxfordbiodynamics

Board restructure to support future growth

Press Release

by oxfordbiodynamics

Oxford BioDynamics to present at BioTech Pharma Summit: Liquid Biopsy 2020 in Lisbon, Portugal

Press Release

by oxfordbiodynamics

Oxford Biodynamics Plc enters into master service agreement with world leading US pharmaceutical company to evaluate EpiSwitch™ biomarkers

Press Release

by oxfordbiodynamics

Final Results for year ended 30 September 2019

Press Release

by oxfordbiodynamics

Development and validation of baseline predictive biomarkers for response to immuno-checkpoint treatments in the context of multiline and multitherapy cohorts using EpiSwitch™ epigenetic profiling

SITC, J. Immunotherapy Cancer 7, 282 (2019) P143

by oxfordbiodynamics

Development and validation of baseline predictive biomarkers for response to avelumab in second-line (2L) non-small cell lung cancer(NSCLC) using EpiSwitch™ epigenetic profiling

SITC, J. Immunotherapy Cancer 7, 282 (2019) P142

by oxfordbiodynamics

Oxford BioDynamics’ EpiSwitch™ Featured in Presentations on Development and Validation of Blood-Based Predictive Biomarkers in Immune Checkpoint Inhibitor Programs

Journal articles P142

Journal articles P143

Press Release

Links to top articles -

Chase

Seeking Alpha

MarketWatch

MorningStar

PR Newswire

Associated Press

Finanzen.net

Yahoo! Finance

Daily Herald

Buffalo News

 

by oxfordbiodynamics